Business Context and Reporting Period
Company: Insight Molecular Diagnostics Inc. (formerly Oncocyte Corporation; Ticker: IMDX)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: iMDx is a diagnostics technology company focused on organ transplant and oncology therapy selection/monitoring. In June 2025, the company rebranded and relocated its headquarters from Irvine, California, to Nashville, Tennessee. The company operates a CLIA-certified laboratory in Nashville and a research lab in Göttingen, Germany.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6M 2025 | 6M 2024 |
|---|---|---|---|---|
| Net Revenue | $518 | $104 | $2,656 | $280 |
| Gross Profit | $350 | $50 | $1,675 | $95 |
| Net Loss | $(9,742) | $(4,530) | $(16,413) | $(13,659) |
| Loss Per Share (Basic/Diluted) | $(0.30) | $(0.36) | $(0.57) | $(1.32) |
| Cash and Cash Equivalents | $24,287 | $8,636 | $24,287 | $10,956 |
| Restricted Cash | $1,700 | $1,700 | $1,700 | $1,700 |
| Total Assets | $50,517 | $35,081 | $50,517 | $35,081 |
| Accumulated Deficit | $(366,952) | $(350,539) | $(366,952) | $(350,539) |
Liquidity: As of June 30, 2025, the company held $24.3 million in cash and cash equivalents. Management believes this is sufficient to meet operating requirements for at least the next twelve months.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 398% quarter-over-quarter (Q2 2025 vs. Q2 2024) and 849% year-to-date. This was driven primarily by Laboratory Services revenue, which grew from $104k to $494k in Q2. The company also recorded its first revenue from Kitted Products ($24k) in Q2 2025.
- Operating Expenses: Total operating expenses increased significantly due to higher R&D ($3.3M vs $2.5M in Q2 2024) and Sales & Marketing ($1.5M vs $0.9M in Q2 2024) costs associated with commercializing transplant and oncology products.
- Contingent Consideration: A non-cash loss of $2.8 million was recorded in Q2 2025 due to a change in the fair value of contingent consideration liabilities (related to IGI and Chronix acquisitions), compared to a gain of $1.0 million in Q2 2024.
- Capital Raise: In February 2025, the company completed a registered direct offering and private placement raising approximately $29.1 million in gross proceeds ($28.7 million net), significantly boosting cash reserves.
Guidance, Outlook, and Risks
- Commercialization: The company expects to begin commercializing its oncology product line (including DetermaIO) over the next 9 months. GraftAssureCore (Kidney) is commercially available, and the company received a positive coverage decision in May 2025 boosting the reimbursement rate to $2,753 per result.
- Strategic Partnership: iMDx has a global strategic partnership with Bio-Rad Laboratories to develop and commercialize RUO and IVD kitted transplant products. The company is dependent on Bio-Rad for certain operations and future performance.
- Risks:
- Reimbursement: Future revenue is heavily dependent on maintaining and expanding Medicare reimbursement coverage. A draft LCD published in July 2025 proposes capping the number of surveillance tests, which could impact future revenue.
- Liquidity: The company has incurred operating losses since inception and expects to continue doing so. Future capital needs may require additional equity financing, resulting in dilution.
- Regulatory: Kitted tests require FDA clearance for clinical use. Delays in regulatory approval could hinder commercialization.
Investor Verification Checklist
- Customer Concentration: Verify the sustainability of Laboratory Services revenue, as one customer represented approximately 95% of accounts receivable and 99% of revenue for the six months ended June 30, 2025.
- Contingent Consideration Liability: Review the fair value assumptions for the $41.6 million contingent consideration liability, as changes in these estimates significantly impact net loss.
- Reimbursement Policy Changes: Monitor the outcome of the July 2025 draft LCD regarding test caps for GraftAssureCore, as this could materially affect future revenue projections.
- Bio-Rad Dependency: Assess the risks associated with the strategic partnership and dependency on Bio-Rad for instrument supply and commercialization.
- Going Concern: While management asserts sufficient cash for 12 months, verify the timeline for achieving profitability given the high burn rate and accumulated deficit of $367 million.